Headache News and Research

Latest Headache News and Research

Sandia engineers aim to develop autonomous device to passively monitor mosquito-borne diseases

Mosquitoes are deadly efficient at spreading disease. Despite vaccines and efforts to eradicate the pesky insects, they continue to infect humans with feared diseases like Zika virus, malaria and West Nile virus.

22 Mar 2016

Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

On Friday, March 18, the U.S. Food and Drug Administration approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs. Anthim is also approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate.

21 Mar 2016

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe.

15 Mar 2016

Hemispheric and thalamic volumes point to electrical epilepticus during sleep

Early assessment of hemispheric and thalamic volumes in children with polymicrogyria and epilepsy can reliably predict the risk of continuous spike-and-wave complexes during sleep, a study indicates.

10 Mar 2016

New FDA approval expands use of AstraZeneca's Faslodex for women with HR+, HER2- metastatic breast cancer

AstraZeneca today announced that the US Food and Drug Administration has approved a new indication in the US, expanding the use of Faslodex (fulvestrant) to include use in combination with Ibrance (palbociclib).

7 Mar 2016

Idelvion approved for use in children and adults with Hemophilia B

The U.S. Food and Drug Administration today approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion protein product to be approved, and the second Factor IX fusion protein product approved in the U.S. that is modified to last longer in the blood.

7 Mar 2016

Pregnant women with acute migraine more likely to experience adverse birth outcomes

Women who have acute migraine attacks that are severe enough to prompt them to seek care may be more likely to have complications when giving birth, including preterm delivery, preeclampsia and low birthweight. Women 35 and older were seven times more likely to have these complications.

4 Mar 2016

Antidepressant paroxetine suppresses inflammation in people with HIV-related cognitive impairment

In a small, placebo-controlled clinical trial, Johns Hopkins physicians report that the antidepressant paroxetine modestly improves decision-making and reaction time, and suppresses inflammation in people with HIV-associated cognitive impairment. The researchers say they believe this is the first time that a SSRI (selective serotonin reuptake inhibitor) has been shown to improve key measures of cognition in people with HIV in a controlled study.

26 Feb 2016

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration seeking approval for the use of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] to treat children under the age of 12 with hemophilia A and for use in surgical settings.

26 Feb 2016

Study: Most Ebola survivors experience brain symptoms more than six months after initial infection

Most of the 82 Ebola survivors in a new study from the world's largest Ebola outbreak had brain symptoms more than six months after the initial infection. The preliminary results will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.

25 Feb 2016

Study: Migraine, tension-type headaches may share genetic links with IBS

Migraine and tension-type headaches may share genetic links with irritable bowel syndrome (IBS), according to a preliminary study released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.

24 Feb 2016

ViiV Healthcare presents positive results from LATTE-2 study at CROI

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented positive results from the LATTE-2 study at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. Headline results were announced in November 2015.

24 Feb 2016

Pfizer’s IBRANCE (palbociclib) now approved for use in women with HR+, HER2- metastatic breast cancer

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy.

23 Feb 2016

Worsening migraine no reason to halt dihydroergotamine infusion

Worsening of headache during intravenous dihydroergotamine treatment for chronic migraine does not mean that the therapy will be unsuccessful, say researchers.

12 Feb 2016

Protein Sciences, UNIGEN agree to supply Flublok influenza vaccine for the U.S. market from Japan

Protein Sciences Corporation (Meriden, CT and Pearl River, NY) and UMN Pharma Inc. (Akita, Akita prefecture, Japan) announced today that Protein Sciences and UNIGEN Inc., a joint venture of UMN and IHI Corporation (Koto-ku, Tokyo, Japan), entered into an agreement to source bulk Flublok influenza vaccine from Japan for the U.S. market.

12 Feb 2016

Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter and year ended December 31, 2015.

12 Feb 2016

UW-Madison research team starts work on Zika virus infection

In October, when David O'Connor last visited Brazil as part of a decade-long research program studying drug-resistant strains of HIV, one of his Brazilian collaborators had a request.

11 Feb 2016

Mayo Clinic researchers discover new bacterial species that triggers Lyme disease in people

Mayo Clinic researchers, in collaboration with the Centers for Disease Control and Prevention and health officials from Minnesota, North Dakota and Wisconsin, have discovered a new bacterial species that causes Lyme disease in people. The new species has been provisionally named Borrelia mayonii. Prior to this finding, the only species believed to cause Lyme disease in North America was Borrelia burgdorferi.

9 Feb 2016

UI researchers remind US doctors to watch for two diseases that could be passed from mother to child

While world health leaders race to contain the spread of the mosquito-borne Zika virus in the Americas, researchers at the University of Iowa are reminding doctors in the United States to be on the lookout for two other vector-borne and potentially life-threatening diseases that can be passed from mother to child through the placenta.

30 Jan 2016

Zepatier receives FDA approval for treatment of chronic HCV genotypes 1 and 4 infections

The U.S. Food and Drug Administration today approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients.

29 Jan 2016

Headache News and Research

Latest Headache News and Research

Sandia engineers aim to develop autonomous device to passively monitor mosquito-borne diseases

Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Hemispheric and thalamic volumes point to electrical epilepticus during sleep

New FDA approval expands use of AstraZeneca's Faslodex for women with HR+, HER2- metastatic breast cancer

Idelvion approved for use in children and adults with Hemophilia B

Pregnant women with acute migraine more likely to experience adverse birth outcomes

Antidepressant paroxetine suppresses inflammation in people with HIV-related cognitive impairment

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Study: Most Ebola survivors experience brain symptoms more than six months after initial infection

Study: Migraine, tension-type headaches may share genetic links with IBS

ViiV Healthcare presents positive results from LATTE-2 study at CROI

Pfizer’s IBRANCE (palbociclib) now approved for use in women with HR+, HER2- metastatic breast cancer

Worsening migraine no reason to halt dihydroergotamine infusion

Protein Sciences, UNIGEN agree to supply Flublok influenza vaccine for the U.S. market from Japan

Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

UW-Madison research team starts work on Zika virus infection

Mayo Clinic researchers discover new bacterial species that triggers Lyme disease in people

UI researchers remind US doctors to watch for two diseases that could be passed from mother to child

Zepatier receives FDA approval for treatment of chronic HCV genotypes 1 and 4 infections

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Headache News and Research

Latest Headache News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in